BAYN.DE Bayer XETRA pre-market 20 Feb 2026 EUR 45.58: settlement news lifts activity

BAYN.DE stock opened pre-market at EUR 45.58 on 20 Feb 2026 after Bayer’s proposed glyphosate settlement drew heavy trading and a spike in volume. The stock shows volume 3,957,644 versus an average of 3,529,614, and intraday range EUR 45.11–46.33. Investors are weighing litigation cash outflows against steady cash generation from Pharmaceuticals and Crop Science, making BAYN.DE stock a top pick in today’s most active list on XETRA.

Price and market snapshot for BAYN.DE stock

Bayer (BAYN.DE) trades on XETRA in EUR with market cap €44.77B and shares outstanding 982,424,082. Today’s pre-market price is EUR 45.58, prior close EUR 45.81, and open EUR 45.80. Year high is EUR 46.89 and year low EUR 18.38, reflecting a large recovery over 12 months of +113.97%. Trading is elevated with relative volume 1.12, signalling outsized attention this session.

Key fundamentals and valuation metrics for BAYN.DE stock

BAYN.DE shows EPS -0.20 and a negative PE -227.87, driven by recent non-operating items and legal provisions. Price/Book is 1.53, Price/Sales 0.98, and Free Cash Flow Yield about 8.72%. Debt to Equity stands at 1.34 and interest coverage is 2.91, highlighting leverage pressure. Revenue per share TTM is 46.69 and book value per share is 30.23, supporting the stock’s current valuation despite headline risks.

Technical picture and intraday signals on BAYN.DE stock

Technicals are mixed but not extreme: RSI 55.31 indicates neutral momentum and ADX 47.64 signals a strong trend. Bollinger middle band sits at EUR 45.72 with upper 47.86 and lower 43.58. MACD histogram is slightly negative (MACD 1.51, Signal 1.80), suggesting short-term consolidation. Active traders will watch a break above EUR 46.89 to confirm continuation or a fall below EUR 45.11 to test support.

Catalysts, risks and BAYN.DE stock news flow

Near-term catalyst is the proposed glyphosate settlement — Bayer disclosed a ~USD 7.25B framework that moved markets and reversed gains the prior session. Litigation resolution would reduce headline risk but pressure near-term cash. Upcoming earnings announcement is scheduled for 2026-03-04, which could reframe guidance. Key risks include further legal charges, crop-science cycle weakness, and high net debt (enterprise value €78.91B) relative to EBITDA. For sources see Reuters and The Wall Street Journal.

Meyka AI grade and BAYN.DE stock technical analysis

Meyka AI rates BAYN.DE with a score of 68.03 out of 100 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The model notes strong free cash flow per share €4.01 but flags leverage (netDebt/EBITDA 5.53) and volatile net income. Traders should treat the grade as data-driven context, not financial advice.

Price targets, model forecasts and trading guidance for BAYN.DE stock

Meyka AI’s forecast model projects short-term targets: monthly EUR 49.38 (implied upside 8.34% vs EUR 45.58) and quarterly EUR 59.96 (implied upside 31.55%). We propose a conservative price target EUR 43.00, base EUR 50.00, and bullish EUR 62.00, based on cash-flow valuation and potential litigation resolution. Forecasts are model-based projections and not guarantees; adjust position size given leverage and headline volatility. See Bayer profile on Meyka: BAYN.DE on Meyka.

Final Thoughts

BAYN.DE stock is the most active name on XETRA pre-market as investors react to a proposed USD 7.25B glyphosate settlement and upcoming earnings on 2026-03-04. At EUR 45.58, the stock trades above its 50-day average EUR 40.64 and well above the 200-day average EUR 30.74, reflecting a strong recovery since last year. Fundamentals show solid free cash flow yield 8.72% and Price/Book 1.53, but high net debt (enterprise value €78.91B) and negative EPS temper the case for a full-risk buy. Meyka AI’s model projects a near-term target of EUR 49.38 (+8.34%) and a quarterly scenario at EUR 59.96 (+31.55%), while we set a conservative target EUR 43.00 and a bullish case EUR 62.00. Use tight risk controls: consider phased entry or hedged exposure given litigation sensitivity. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.